208 related articles for article (PubMed ID: 30088662)
1. Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Li J; Gu J
J Clin Pharmacol; 2019 Jan; 59(1):45-54. PubMed ID: 30088662
[TBL] [Abstract][Full Text] [Related]
2. Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Yang W; Li S; Yang Q
Medicine (Baltimore); 2019 May; 98(20):e15731. PubMed ID: 31096532
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
5. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
6. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
9. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
11. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Ge Y; Zhang H; Weygant N; Yao J
Front Pharmacol; 2021; 12():640099. PubMed ID: 34447305
[No Abstract] [Full Text] [Related]
12. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.
Wang Y; Kong D; Wang C; Chen J; Li J; Liu Z; Li X; Wang Z; Yao G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820967454. PubMed ID: 33084525
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.
Manohar S; Kompotiatis P; Thongprayoon C; Cheungpasitporn W; Herrmann J; Herrmann SM
Nephrol Dial Transplant; 2019 Jan; 34(1):108-117. PubMed ID: 29762725
[TBL] [Abstract][Full Text] [Related]
15. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Wang Y; Ma Z; An Z; Zhang Y; Feng X; Yu X
Cancer Med; 2023 Feb; 12(3):2227-2237. PubMed ID: 35986570
[TBL] [Abstract][Full Text] [Related]
16. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2020; 1244():235-246. PubMed ID: 32301018
[TBL] [Abstract][Full Text] [Related]
17. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Xu M; Nie Y; Yang Y; Lu YT; Su Q
Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
[TBL] [Abstract][Full Text] [Related]
18. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Zhang Y; La B; Liang B; Gu Y
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833153
[TBL] [Abstract][Full Text] [Related]
19. Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.
Zhang S; Liang F; Zhu J; Chen Q
Mol Cancer Ther; 2017 Aug; 16(8):1588-1595. PubMed ID: 28446641
[TBL] [Abstract][Full Text] [Related]
20. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
Li J; Yan H
Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
